Status:

UNKNOWN

Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients

Lead Sponsor:

Medical Center Alkmaar

Conditions:

Colon Carcinoma

Eligibility:

MALE

18-75 years

Phase:

NA

Brief Summary

Rationale: It is well known that insulin resistance occurs after mediocre and intensive surgery, such as colon cancer surgery. Disturbances in insulin action negatively affect the postoperative recove...

Eligibility Criteria

Inclusion

  • Age between 18 and 75 years
  • Colon cancer patients scheduled for elective open abdominal surgery
  • Capable of giving informed consent

Exclusion

  • Patients who are participating in another clinical trial
  • Unable to receive oral intake
  • Major malabsorption disorder of the gut
  • Patients with diabetes mellitus
  • BMI above 30 kg/m2
  • Use of certain medication: thyroid medication, corticosteroids, diuretic medication
  • Known bleeding disorders or increased PTT and or APTT
  • Any medical condition except for colon cancer

Key Trial Info

Start Date :

December 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 1 2013

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT00922688

Start Date

December 1 2010

End Date

May 1 2013

Last Update

July 21 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical Center Alkmaar

Alkmaar, North Holland, Netherlands, 1815 JD

Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients | DecenTrialz